Therapeutic potential of JAK2 inhibitors

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens

(2009) Stefan N. Constantinescu   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

(2009) Damla Olcaydu et al.   NATURE GENETICS

A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms

(2009) Outi Kilpivaara et al.   NATURE GENETICS

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

(2009) Amy V Jones et al.   NATURE GENETICS

Myeloproliferative disorders

(2008) R. L. Levine et al.   BLOOD

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms

(2008) C. S. Tam et al.   BLOOD

Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

(2008) Ifat Geron et al.   CANCER CELL

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers

(2008) E. G. Jeong et al.   CLINICAL CANCER RESEARCH

Phenotypic variability within the JAK2 V617F-positive MPD: Roles of progenitor cell and neutrophil allele burdens

(2008) Alison R. Moliterno et al.   EXPERIMENTAL HEMATOLOGY

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Genetic complexity of myeloproliferative neoplasms

(2008) R Kralovics   LEUKEMIA

Miscreant myeloproliferative disorder stem cells

(2008) C H M Jamieson et al.   LEUKEMIA

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features

(2008) N C P Cross et al.   LEUKEMIA

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

(2008) T L Lasho et al.   LEUKEMIA

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science

(2008) O Kilpivaara et al.   LEUKEMIA

JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies

(2008) William Vainchenker et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Mining for JAK–STAT mutations in cancer

(2008) Stefan N. Constantinescu et al.   TRENDS IN BIOCHEMICAL SCIENCES